CytomX Therapeutics, Inc. (CTMX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US23284F1057
CytomX Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 76.20 m USD |
| Operating income | -22.36 m USD |
| EBIT | -22.34 m USD |
| Net income | -17.37 m USD |
| Diluted EPS – continuing operations | -0.15 USD |
Full history since 2012, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About CytomX Therapeutics, Inc.
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California.
More stocks
- Shandong Longji Machinery Co Ltd (002363.SZ)
- Zhongxing Shenyang Commercial Building Group Co Ltd (000715.SZ)
- Zhejiang Jinfei Kaida Wheel Co Ltd (002863.SZ)
- Tederic Machinery Co Ltd (603289.SS)
- STAR GROUP, L.P. (SGU)
- Tower Ltd (TWR.AX)
- Ningbo Gaofa Automotive Ctrl (603788.SS)
- Samkang M&T Co Ltd (100090.KS)
- Diversified Royalty Corp (DIV.TO)
- TianJin JinRong TianYu Precision Machinery Inc. (300988.SZ)
- Jiangnan Yifan Motor Co.Ltd (301023.SZ)
- Daesang Corp (001680.KS)
Not investment advice. All data without warranty, price as of 10.11.2026. Details in the risk notice.